EyePoint

On this , we proudly honor the exceptional principal investigators driving our pivotal Phase 3 clinical programs in wet AMD and DME.

We appreciate your contributions as we work toward a new possibility—bringing the first sustained release TKI to market for patients. https://eyepoint.bio/our-programs/?utm_source=fb&utm_medium=organic_mar26&utm_campaign=nationaldrday

Even with current anti-VEGF treatments, many people living with DME still face ongoing vision loss, underscoring the critical need for more durable therapies that also address inflammation.

We’re proud to be paving the way for possible new treatment options with the first and only investigational sustained release TKI now in Phase 3 clinical trials for DME.

Discover more about our pivotal Phase 3 program and our commitment to advancing care for DME patients: https://eyepoint.bio/our-programs/?utm_source=fb&utm_medium=organic_mar26&utm_campaign=dmeprogram

We couldn’t let pass without celebrating the amazing people who make EyePoint great! Our Employee Appreciation Extravaganza brought our team together for a week of fun, food, and community service with Life Science Cares Boston – along with EyePoint-branded treats for our remote team!

Our people are the heart of everything we do, living our core values every day. Thank you!

Are you ready to with EyePoint? We’re always looking for passionate individuals to join our team. Learn more: https://eyepoint.bio/working-at-eyepoint/?utm_source=fb&utm_medium=organic_mar26&utm_campaign=ead

EyePoint announces the first patients dosed in both of our global Phase 3 clinical trials for the treatment of diabetic macular edema (DME).

🔎The only sustained release TKI in Phase 3 clinical trials for DME
2️⃣ Global, non-inferiority clinical trials: COMO & CAPRI
📈 Topline data expected 2H 2027

👉 Read more here: https://investors.eyepoint.bio/news-releases/news-release-details/eyepoint-announces-first-patients-dosed-both-global-phase-3?utm_source=fb&utm_medium=organic_mar26&utm_campaign=dmefpd

Wet AMD is the leading cause of vision loss and irreversible blindness in people over 50. The high treatment burden often leads to missed appointments and possible irreversible vision loss.

This AMD and Low Vision Awareness Month, reinforces our commitment to developing longer-acting therapies to improve vision and reduce the treatment burden for patients and caregivers.

We are a proud partner of Prevent Blindness, whose advocacy plays a vital role in the fight against .

Join us in recognizing :

https://preventblindness.org/2026-amd-low-vision-month/

Please join us in welcoming Michael Campbell to EyePoint as our new Chief Commercial Officer!

Mike brings over 30 years of commercial leadership experience in both biotech and large pharma and a proven track record of successful product launches, with oversight of prominent ophthalmology franchises.

With topline data from our Phase 3 pivotal wet AMD program expected beginning in mid-2026, his deep commercial expertise will be instrumental as we work towards a new possibility - bringing the first sustained release TKI to market for patients.

Read the full announcement: https://investors.eyepoint.bio/news-releases/news-release-details/eyepoint-appoints-michael-campbell-chief-commercial-officer?utm_source=fb&utm_medium=organic_feb26&utm_campaign=cco

When it comes to matters of sight, innovation is our vision.

We’re advancing a potential novel multi-mechanism of action for wet AMD and DME - the largest retinal disease markets where there is a significant need for new therapeutic options.

See more on our programs: https://eyepoint.bio/our-programs/?utm_source=fb&utm_medium=organic_feb26&utm_campaign=multimoatki

This and Low Vision Month, we’re proud to support Prevent Blindness in our shared commitment to improving the lives of patients with serious retinal diseases.

Find resources for patients and professionals on living with low vision, facts and stats on eyes, and explore advocacy initiatives at https://preventblindness.org/

As we close out the year, we were grateful to celebrate the incredible EyePoint team at our annual holiday party.

Every day, their dedication, teamwork, and creativity drive our mission to develop innovative therapeutics to improve the lives of patients with serious retinal diseases.

Together, we’ve reached major milestones and progressed forward – setting the stage for even greater achievements in the year ahead.

Wishing everyone a joyful holiday season!

What an incredible week at ! Our team had the chance to connect with retina specialists, researchers, and other leaders who are pushing the field forward. We’re grateful for the conversations, collaboration, and shared commitment to advancing retinal care.

Some highlights from the meeting:
•Shared the results from our Phase 2 DAVIO 2 wet AMD and VERONA DME clinical trials
•Engaged in meaningful discussions on current treatment burden in wet AMD and DME, and the potential of sustained-delivery TKIs for retinal care
•Made great connections with meeting attendees with several interactions at our booth

Thank you to everyone who joined us and helped make this meeting so impactful. We’re already looking forward to next year!